Modelling the economic value of cross- and sustained-protection in vaccines against cervical cancer.

abstract：BACKGROUND:Efficient use of government funding has been increasingly relevant for the success and sustainability of ongoing health-system reform in China; however, as there is no generic substitution policy, patients and basic health-insurance programs pay more for public-preferred brand originators. Such phenomenon is...

journal_title：Journal of medical economics

authors： Sun J,Ren L,Wirtz V

更新日期：2016-09-01 00:00:00

abstract：OBJECTIVES:This study reviewed patient characteristics, management, and medical costs of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDSs) in Spanish hospitals. METHODS:Data were extracted from the Spanish Ministry of Health records via a claims database containing patient records from 192 private and ...

journal_title：Journal of medical economics

authors： Marsà A,Ascanio M,Diaz-García J,Darbà J

更新日期：2020-11-02 00:00:00

abstract：BACKGROUND:Bipolar 1 disorders (BPD) are a chronic disorder with prevalence rates of up to 2.6% of the adult population or higher and appreciable direct and indirect costs. As a result, these are a concern to health authorities especially given the low age of onset. Consequently, there is a need to treat BPD patients w...

journal_title：Journal of medical economics

authors： Godman B

更新日期：2015-01-01 00:00:00

abstract：INTRODUCTION:The patient cost burden of oral anticancer medicines has been associated with prescription abandonment, delayed treatment initiation, and poorer health outcomes in the US. Since 2011, several small molecule tyrosine kinase inhibitors have been approved for the treatment of non-small cell lung cancer (NSCLC...

journal_title：Journal of medical economics

authors： Seetasith A,Wong W,Tse J,Burudpakdee C

更新日期：2019-05-01 00:00:00

abstract：INTRODUCTION:Myelofibrosis is a non-frequent chronic myeloproliferative Philadelphia-negative chromosome neoplasm. It is a heavy incapacitating orphan disease and associated with high morbidity and mortality. In this context, indirect and non-medical costs are expected to be high. The main objective of this project is ...

journal_title：Journal of medical economics

authors： Gimenez E,Besses C,Boque C,Velez P,Kerguelen A,Cervantes F,Ferrer-Marin F,Perez-Encinas M,Rodriguez M,Gonzalez JD,Calzada R,Hernandez-Boluda JC

更新日期：2014-06-01 00:00:00

abstract：OBJECTIVE:To construct a value-based healthcare system for rural Chinese hypertensive patients through an increasing outpatient care reimbursement ratio. METHODS:This comparative study sampled two similar counties, Dangyang County and Zhijiang County, in Hubei Province of China, as the intervention group and the contr...

journal_title：Journal of medical economics

authors： Miao Y,Yuan X,Gu J,Zhang L,He R,Sandeep S,Wu J

更新日期：2019-03-01 00:00:00

abstract：OBJECTIVE:To assess the economic impact of initial and repeat hospitalizations associated with acute coronary syndrome (ACS) over 1 year (2009). DESIGN AND METHODS:National- and state-level data on length of stay (LOS) and related charges for ACS-associated hospital admissions were assessed using two Healthcare Utiliz...

journal_title：Journal of medical economics

authors： LaMori JC,Shoheiber O,Dudash K,Crivera C,Mody SH

更新日期：2014-03-01 00:00:00

abstract：OBJECTIVE:To compare 1-year costs and benefits of dapagliflozin (DAPA), a sodium-glucose cotransporter-2 (SGLT-2) inhibitor, with those of other treatments for type 2 diabetes (T2D), such as glucagon-like peptide-1 receptor agonists (GLP-1RAs), sulfonylureas (SUs), thiazolidinediones (TZDs), and dipeptidyl peptidase-4 ...

journal_title：Journal of medical economics

authors： Chakravarty A,Rastogi M,Dhankhar P,Bell KF

更新日期：2018-05-01 00:00:00

abstract：OBJECTIVE:To assess the cost-effectiveness (CE) of the originator follitropin-α (Gonal-F) in patients undergoing a medically assisted reproduction (MAR) program in comparison to its biosimilars Bemfola and Ovaleap in a French context. METHODS:A CE model was developed for France with a National Health Service (NHS) per...

journal_title：Journal of medical economics

authors： Grynberg M,Murphy C,Doré C,Fresneau L,Paillet S,Petrica N,Frédérique M,Ravonimbola H

更新日期：2018-11-21 00:00:00

abstract：BACKGROUND:Currently the majority of cancer deaths occur in low- and middle-income countries, where there are appreciable funding concerns. In Kenya, most patients currently pay out of pocket for treatment, and those who are insured are generally not covered for the full costs of treatment. This places a considerable b...

journal_title：Journal of medical economics

authors： Atieno OM,Opanga S,Martin A,Kurdi A,Godman B

更新日期：2018-09-01 00:00:00

abstract：OBJECTIVE:To study outcomes of multiple sclerosis (MS) patients treated with either glatiramer acetate (Copaxone) or interferon beta-1a for once-weekly, intramuscular administration (Avonex). METHODS:An 'intent-to-treat' (ITT) cohort (n=1282) was established, consisting of patients diagnosed with MS who began therapy ...

journal_title：Journal of medical economics

authors： Castelli-Haley J,Oleen-Burkey MA,Lage MJ,Johnson K

更新日期：2010-01-01 00:00:00

abstract：OBJECTIVE:Epilepsy surgery is one of the most effective treatments in modern medicine. Yet, it remains largely under-utilized, in spite of its proven efficacy. The referrals for epilepsy surgery are often delayed until it is too late to prevent the detrimental psychosocial effects of refractory seizures. The reluctance...

journal_title：Journal of medical economics

authors： Edwards JC,Sobel RS,Bonilha L

更新日期：2018-05-01 00:00:00

abstract：OBJECTIVE:To estimate the economic implications of introducing dabigatran etexilate ('dabigatran') for anti-coagulation therapy in Danish patients with non-valvular atrial fibrillation based on results of the RE-LY trial. METHODS:The lifetime cost and outcomes of dabigatran and warfarin were estimated using a previous...

journal_title：Journal of medical economics

authors： Langkilde LK,Bergholdt Asmussen M,Overgaard M

更新日期：2012-01-01 00:00:00

abstract：OBJECTIVES:More than 1.5 million patients worldwide are affected by bone metastases. Patients with bone metastases frequently develop skeletal-related events (SREs, including radiation to bone, non-vertebral fracture, vertebral fracture, surgery to bone, and spinal cord compression) that are associated with high health...

journal_title：Journal of medical economics

authors： Body JJ,Chevalier P,Gunther O,Hechmati G,Lamotte M

更新日期：2013-01-01 00:00:00

abstract：OBJECTIVE:This study compared real-world treatment patterns and healthcare costs among biologic-naive psoriasis patients initiating apremilast or biologics. METHODS:A retrospective cohort study was conducted using the Optum Clinformatics™ claims database. Patients with psoriasis were selected if they had initiated apr...

journal_title：Journal of medical economics

authors： Wu JJ,Pelletier C,Ung B,Tian M

更新日期：2019-04-01 00:00:00

abstract：OBJECTIVE:The only effective treatment for severe aortic stenosis (AS) is valve replacement. However, many patients with co-existing conditions are ineligible for surgical valve replacement, historically leaving medical management (MM) as the only option which has a poor prognosis. Transcatheter Aortic Valve Replacemen...

journal_title：Journal of medical economics

authors： Hancock-Howard RL,Feindel CM,Rodes-Cabau J,Webb JG,Thompson AK,Banz K

更新日期：2013-01-01 00:00:00

abstract：BACKGROUND:Alemtuzumab and natalizumab are approved as second-line therapies for relapsing-remitting multiple sclerosis (RRMS) patients in Iran who have shown an inadequate response to other disease-modifying therapy (DMT). In the absence of head-to-head trials, evaluations based on decision analytic modeling may be a ...

journal_title：Journal of medical economics

authors： Taheri S,Sahraian MA,Yousefi N

更新日期：2019-01-01 00:00:00

abstract：OBJECTIVE:In patients with significant mitral regurgitation (MR) at high risk of mortality and morbidity from mitral valve surgery, transcatheter mitral valve repair with the MitraClip System is associated with a reduction in MR and improved quality-of-life and functional status compared with baseline. The objective wa...

journal_title：Journal of medical economics

authors： Cameron HL,Bernard LM,Garmo VS,Hernandez JB,Asgar AW

更新日期：2014-08-01 00:00:00

abstract：BACKGROUND:EOX (epirubicin, oxaliplatin, Xeloda; capecitabine) and FOLFOX4 (5-fluorouracil (5-FU), leucovorin, oxaliplatin) are the common chemotherapy regimens used in the treatment of advanced gastric cancer (aGC) in Hong Kong. This study aimed to compare the costs of these therapies for aGC patients from both the he...

journal_title：Journal of medical economics

authors： Zhou KR,Cheng A,Ng WT,Kwok TY,Yip EY,Yao R,Leung PY,Lee VW

更新日期：2017-05-01 00:00:00

abstract：:Aims: This article aimed to examine the cost-effectiveness of rivaroxaban in comparison to warfarin for stroke prevention in Japanese patients with non-valvular atrial fibrillation (NVAF), from a public healthcare payer's perspective.Materials and methods: Baseline event risks were obtained from the J-ROCKET AF trial ...

journal_title：Journal of medical economics

authors： Hori M,Tanahashi N,Akiyama S,Kiyabu G,Dorey J,Goto R

更新日期：2020-03-01 00:00:00

abstract：:Aims: To assess healthcare resource utilization (HCRU) and costs in patients with non-small cell lung cancer treated with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors afatinib or erlotinib as first-line treatment.Materials and methods: This retrospective analysis used data from three large ad...

journal_title：Journal of medical economics

authors： Samuelsen C,Lim J,Golembesky A,Shrestha S,Wang L,Griebsch I

更新日期：2020-01-01 00:00:00

abstract：:Aims: To assess rates of surgical treatment, post-surgical complications, reoperations, and reimbursement in patients with clavicle fractures and acromioclavicular (AC) dislocations. Materials and methods: This US retrospective study used data from patients with ≥1 diagnosis of clavicle fracture or AC dislocation (ind...

journal_title：Journal of medical economics

authors： Putnam M,Vanderkarr M,Nandwani P,Holy CE,Chitnis AS

更新日期：2019-09-01 00:00:00

abstract：AIM:This analysis assessed the direct medical costs of newly-diagnosed, temozolomide (TMZ)-treated glioblastoma (GBM) from the perspective of a US commercial setting. MATERIALS AND METHODS:The analysis included subjects identified from the IMS PharMetrics LifeLink Plus™ claims database from January 1, 2008 to August 3...

journal_title：Journal of medical economics

authors： Jiang S,Hill K,Patel D,Waldeck AR,Botteman M,Aly A,Norden AD

更新日期：2017-12-01 00:00:00

abstract：OBJECTIVE:To estimate health-related quality of life (HRQoL) in non-growth hormone deficient (GHD) small for gestational age (SGA) children before and after growth hormone (GH) treatment to adult height (AH). METHODS:This was a multicentre, two-arm trial. Following an initial 2-year double-blind study period, patients...

journal_title：Journal of medical economics

authors： Bannink E,Djurhuus CB,Christensen T,Jøns K,Hokken-Koelega A

更新日期：2010-01-01 00:00:00

abstract：OBJECTIVE:Cost-effectiveness analyses of new treatments for cardiovascular disease frequently require input parameters whose values are known with uncertainty due to limited data. The objective of this paper is to examine the extent to which published sensitivity analyses addressing this uncertainty adhere to Health Te...

journal_title：Journal of medical economics

authors： Mauskopf JA,Boye KS,Schmitt C,McCollam P,Birt J,Juniper MD,Bakhai A

更新日期：2009-06-01 00:00:00

abstract：OBJECTIVE:To compare the persistence and costs of brimonidine versus brinzolamide therapy according to data collected by the UK General Practitioner Research Database (GPRD). METHODS:Patients with diagnoses of ocular hypertension or glaucoma, or treated for glaucoma by surgery or laser therapy were identified. Selecte...

journal_title：Journal of medical economics

authors： Lafuma A,Laurendeau C,Berdeaux G

更新日期：2008-01-01 00:00:00

abstract：OBJECTIVES:To assess the cost effectiveness of palivizumab, a humanised monoclonal antibody, used as prevention against severe respiratory syncytial virus (RSV) infection requiring hospitalisation, in infants with haemodynamically significant congenital heart disease (CHD) in the German healthcare setting. STUDY DESIG...

journal_title：Journal of medical economics

authors： Nuijten M,Lebmeier M,Wittenberg W

更新日期：2009-01-01 00:00:00

abstract：:Background: Adults admitted to hospital with community-acquired pneumonia (CAP) impose significant burden upon limited hospital resources. To achieve early response and possibly early discharge, thus reducing hospital expenditure, the choice of initial antibiotic therapy is pivotal.Methods: A cost-consequences model w...

journal_title：Journal of medical economics

authors： Torres A,Bassetti M,Welte T,Rivolo S,Remak E,Peral C,Charbonneau C,Hammond J,Ansari W,Grau S

更新日期：2020-02-01 00:00:00

abstract：OBJECTIVE:To quantify and compare hospital length of stay (LOS) and costs between hospitalized non-valvular atrial fibrillation (NVAF) patients treated with either apixaban or warfarin via a large claims database. METHODS:Adult patients hospitalized with AF were selected from the Premier Perspective Claims Database (0...

journal_title：Journal of medical economics

authors： Xie L,Vo L,Keshishian A,Price K,Singh P,Mardekian J,Bruno A,Baser O,Kim J,Tan W,Trocio J

更新日期：2016-08-01 00:00:00

abstract：OBJECTIVE:To assess the cost-effectiveness of panitumumab in combination with mFOLFOX6 (oxaliplatin, 5-fluorouracil, and leucovorin) vs bevacizumab in combination with mFOLFOX6 as first-line treatment of patients with wild-type RAS metastatic colorectal cancer (mCRC) in Spain. METHODS:A semi-Markov model was developed...

journal_title：Journal of medical economics

authors： Rivera F,Valladares M,Gea S,López-Martínez N

更新日期：2017-06-01 00:00:00